Using Vasopressin for Septic Shock in Addition to Norepinephrine
Official title: Systematic Adjunction of Vasopressine in Hyperkinetic Septic Shock Patients - A Multicentric RCT
Run by Assistance Publique Hopitaux De Marseille · NCT07052084 · Data updated 2026-11-12
This phase 3 trial tests adding vasopressin to norepinephrine in adults with septic shock to see if it improves blood pressure support.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Assistance Publique Hopitaux De Marseille Academic / other |
| Locations | 3 sites (Aix-en-Provence and 2 other locations) |
| Status | Recruiting |
| Started | March 24, 2026 |
| Main results expected | February 2028 |
| Study ends | February 2028 |
| Registry record updated | October 26, 2026 |
| Trial ID | NCT07052084 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older with septic shock already receiving norepinephrine above 0.3 µg/kg/min for up to 12 hours.
✕Probably not a fit
Patients who do not respond to vasopressin, have contraindications, or have exclusion criteria such as acute coronary syndrome or hyponatremia may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In septic shock, norepinephrine is typically the first-line vasopressor, but higher doses have been linked to worse outcomes. This study evaluates systematic addition of vasopressin as a second-line vasopressor alongside ongoing norepinephrine, to see if it can improve hemodynamic stability and outcomes. Participants are adults with septic shock who are receiving norepinephrine at a dose above 0.3 µg/kg/min for up to 12 hours. The trial uses sodium chloride as part of the intervention alongside vasopressin administration, following established guidelines for refractory shock management.
Why it matters
Potential benefit: If successful, adding vasopressin could improve blood pressure control and survival in septic shock patients.
How similar studies have gone: Vasopressin is already recommended as a second-line vasopressor in refractory shock; previous data support its use, but this trial specifically tests a systematic adjunction strategy in septic shock.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 18 or over * Patient who has consented to take part in the research or patient whose close relative has consented to take part in the research or, failing that, patient being included in an emergency situation * Patient in septic shock with adapted cardiac output * Patient in whom noradrenaline dosage has been greater than 0.3μg/kg/min for less than 12 hours * Patients benefiting from or affiliated to social security Exclusion Criteria: * Patient with acute coronary syndrome * Patient with known history of acute coronary syndrome * Patient with suspected mesenteric ischemia * Patient with hyponatremia \< 130mmol/L, * Known allergy to vasopressin or its excipients * Minors * Pregnant women * Patients under legal guardianship or curatorship * Patients under judicial protection.
Where it's running
-
Centre Hospitalier du Pays d'Aix
Aix-en-Provence, France Recruiting -
Assistance Publique - Hôpitaux de Marseille
Marseille, France Recruiting -
CHU de Nîmes - Carémeau
Nîmes, France Recruiting
Study contacts
- Study coordinator: Gary Duclos, MD
- Email: gary.duclos@ap-hm.fr
- Phone: 04 91 96 55 31
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adjunctive Fludrocortisone in Septic Shock on Hydrocortisone
In septic shock, this trial tests whether adding fludrocortisone (50 mcg or 100 mcg daily) to hydrocortisone improves survival and recovery compared with placebo.
-
Non-invasive hemodynamic guidance for sepsis care on medical wards
This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.
-
Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter
This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.
-
Personalized Fluid Resuscitation in the Emergency Department
This pilot test checks if a quick, non-invasive stroke-volume assessment can help ED doctors tailor IV fluids for septic patients with low blood pressure.
-
Discordance between capillary refill time and oxygen use in septic shock
This study tests whether some septic shock patients can have a normal capillary refill time but still lack tissue oxygen use, to see if that mismatch relates to 28-day survival.
-
Targeting upper-normal magnesium to see if norepinephrine needs drop in septic shock
This trial tests whether keeping magnesium levels at the upper end of normal can reduce the amount and duration of norepinephrine needed in adults with septic shock.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.